SCHEMBL20122870

SCHEMBL20122870

CCn1c2cnccc2c2cc(Cl)cc(-c3cccnc3)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 4/20 0.43
METAP2 P50579 1/20 0.40
KDM5A P29375 1/20 0.40
CYP11B1 P15538 4/20 0.40
CYP11B2 P19099 4/20 0.40
KCNH2 Q12809 1/20 0.39
AOC3 Q16853 1/20 0.39
CYP2C19 P33261 2/20 0.39
CYP2A6 P11509 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2E1 P05181 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2B6 P20813 1/20 0.39
CDC25A P30304 1/20 0.39
CDC25B P30305 1/20 0.39
CYP17A1 P05093 2/20 0.38
CYP1A2 P05177 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP19A1 P11511 1/20 0.38
TBXAS1 P24557 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664279 1.00 ROCK2 (0.43) ROCK2METAP2KDM5ACYP11B1CYP11B2
SCHEMBL30664233 0.89 ROCK2 (0.39) ROCK2METAP2KDM5AKCNH2CYP2C19
SCHEMBL20122911 0.89 ROCK2 (0.39) ROCK2METAP2KDM5AKCNH2CYP2C19
SCHEMBL30664293 0.89 METAP2 (0.44) ROCK2METAP2KDM5AKCNH2CYP1A2
SCHEMBL20122892 0.89 METAP2 (0.44) ROCK2METAP2KDM5AKCNH2CYP1A2
SCHEMBL30664221 0.88 ROCK2 (0.40) ROCK2METAP2KDM5AKCNH2AOC3
SCHEMBL20123010 0.88 ROCK2 (0.40) ROCK2METAP2KDM5AKCNH2AOC3
SCHEMBL20122961 0.87 ROCK2 (0.39) ROCK2METAP2KDM5ACYP1A2DYRK1A
SCHEMBL30664314 0.87 ROCK2 (0.39) ROCK2METAP2KDM5ACYP1A2DYRK1A
SCHEMBL20122943 0.86 ROCK2 (0.40) ROCK2METAP2KDM5ACYP2A6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 ROCK2 1093/4885METAP2 3515/4885KDM5A 888/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 ROCK2 1093/4885METAP2 3515/4885KDM5A 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.